Pierre Blier, MD, PhD
University of Ottawa Institute of Mental Health Research at The Royal, Ottawa, Canada; Department of Psychiatry, McGill University, Montreal, Canada; Department of Psychiatry, University of Ottawa, Ottawa, Canada
Original Research
Levomilnacipran, but Not Duloxetine, Inhibits Serotonin and Norepinephrine Reuptake Throughout Its Therapeutic Range
August 25, 2025
Levomilnacipran and duloxetine are both potent serotonin reuptake inhibitors at all therapeutic regimens for MDD. Potent norepinephrine reuptake inhibition can be achieved from initiation with levomilnacipran, in contrast to...
Original Research
Worsening of Suicidal Ideation During AD Treatment
May 7, 2019
Antidepressants are effective in preventing suicide, but some antidepressant-treated patients experience increased suicidal ideation. Read this article to learn if clinical features and biomarkers can predict worsened suicidal ideation...
Original Research
CAN-BIND-1 Outcomes and Early Response Prediction in MDD
February 5, 2019
Antidepressant medications are often prescribed with little certainty about their potential effectiveness in individual patients. Can early symptom reduction help predict later symptomatic and functional outcomes of antidepressant treatment?...
